Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Curis Inc (CRIS)

Curis Inc (CRIS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Curis: Q4 Earnings Snapshot AP - Thu Feb 8, 7:11AM CST

Curis: Q4 Earnings Snapshot

CRIS : 15.20 (+2.36%)
Curis: Q3 Earnings Snapshot AP - Thu Nov 2, 2023

Curis: Q3 Earnings Snapshot

CRIS : 15.20 (+2.36%)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire - Fri Oct 6, 2023

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

CRIS : 15.20 (+2.36%)
Curis to Present at Upcoming Healthcare Conferences in September PR Newswire - Wed Sep 6, 2023

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4...

CRIS : 15.20 (+2.36%)
Curis: Q2 Earnings Snapshot AP - Thu Aug 3, 2023

Curis: Q2 Earnings Snapshot

CRIS : 15.20 (+2.36%)
Curis Provides Second Quarter 2023 Business Update PR Newswire - Thu Aug 3, 2023

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4...

CRIS : 15.20 (+2.36%)
Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023 PR Newswire - Thu Jul 27, 2023

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4...

CRIS : 15.20 (+2.36%)
FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID PR Newswire - Thu Jul 6, 2023

/PRNewswire/ -- Curis, Inc., (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule triple...

CRIS : 15.20 (+2.36%)
Curis Announces $15.1 Million Registered Direct Offering PR Newswire - Thu Jul 6, 2023

/PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, a triple target inhibitor (IRAK4, FLT3 and CLK)...

CRIS : 15.20 (+2.36%)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire - Fri May 5, 2023

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

CRIS : 15.20 (+2.36%)

Barchart Exclusives

2 'Strong Buy' Cannabis Stocks Set to Gain on Spending Bill Maneuvers Barchart - 1 hour ago
The U.S. cannabis market could be on the cusp of a critical growth catalyst, presenting ripe investment opportunities for those ready to navigate its unique risks. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot